CMMB

Chemomab Therapeutics

3.40 USD
+0.08
2.41%
At close Updated Oct 20, 4:00 PM EDT
Pre-market
After hours
3.45
+0.05
1.47%
1 day
2.41%
5 days
1.49%
1 month
29.28%
3 months
-22.73%
6 months
-26.72%
Year to date
-60.09%
1 year
-47.85%
5 years
-96.41%
10 years
-99.51%
 

About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Employees: 16

0
Funds holding %
of 7,498 funds
0
Analysts bullish %
of 1 analysts
Positive news %
of articles
Price charts implemented using Lightweight Charts™